PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3)

被引:93
作者
Sorbye, Halfdan [1 ,2 ]
Kong, Grace [3 ,4 ]
Grozinsky-Glasberg, Simona [5 ]
机构
[1] Haukeland Hosp, Dept Oncol, Bergen, Norway
[2] Univ Bergen, Dept Clin Sci, Bergen, Norway
[3] Peter MacCallum Canc Ctr, Dept Mol Imaging & Therapeut Nucl Med, Melbourne, Vic, Australia
[4] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia
[5] Hadassah Hebrew Univ Med Ctr, Neuroendocrine Tumor Unit, ENETS Ctr Excellence, Dept Endocrinol & Metab, Jerusalem, Israel
关键词
peptide receptor radionuclide therapy; gastroenteropancreatic; neuroendocrine carcinoma; neuroendocrine tumors; RECEPTOR RADIONUCLIDE THERAPY; RADIOLABELED SOMATOSTATIN ANALOG; ENETS CONSENSUS GUIDELINES; TREATMENT RESPONSE; PROGNOSTIC-FACTORS; TYR(3) OCTREOTATE; GEP-NEN; TUMORS; CARCINOMAS; SURVIVAL;
D O I
10.1530/ERC-19-0400
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Peptide receptor radionuclide therapy (PRRT) is an established treatment for grade 1 and 2 gastroenteropancreatic neuroendocrine tumors with an increased uptake on somatostatin receptor imaging (SRI). Patients with metastatic high-grade (WHO G3) gastroenteropancreatic neuroendocrine neoplasms (NET G3 and NEC) represent a heterogeneous subgroup with poor prognosis and standard platinum-etoposide chemotherapy have limited therapeutic benefit. However, there is promising emerging evidence supporting the effectiveness of PRRT in SRI-positive G3 disease. A review search for studies reporting on PRRT in gastroenteropancreatic neuroendocrine neoplasms G3 was performed: four studies with more than ten cases were found. PRRT was mainly given as second- or third-line treatment in patients with progressive disease. Most patients had a pancreatic primary, 50% had well-differentiated tumors, and most had a Ki-67 <55%. Three studies showed similar results with promising response rates (31-41%) and disease control rates (69-78%). Progression-free survival (11-16 months) and survival (22-46 months) were best concerning patients with a Ki-67 <55%. Progression-free survival was 19 months in NET G3, 11 months for lowNEC (Ki-67 <= 55%) and 4 months for highNEC (Ki-67 >55%). PRRT should be considered for patients with increased uptake on SRI, both in gastroenteropancreatic NET G3 cases and as well as in NEC cases with a Ki-67 21-55%. PRRT for NEC with a Ki-67 >55% is less defined, but could be considered in highly selected cases after response to initial chemotherapy where all residual disease have high uptake on SRI. Dual tracer using 18F-FDG PET/CT and SRI provides important information for patient selection for PRRT in this heterogeneous complex high-grade disease.
引用
收藏
页码:R67 / R77
页数:11
相关论文
共 56 条
  • [31] Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms
    Mizuno, Yuki
    Kudo, Atsushi
    Akashi, Takumi
    Akahoshi, Keiichi
    Ogura, Toshiro
    Ogawa, Kosuke
    Ono, Hiroaki
    Mitsunori, Yusuke
    Ban, Daisuke
    Tanaka, Shinji
    Tateishi, Ukihide
    Tanabe, Minoru
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2018, 144 (06) : 1155 - 1163
  • [32] National comprehensive cancer network, 2019, PLYM M
  • [33] Investigation of receptor radionuclide therapy with 177Lu-DOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index
    Nicolini, Silvia
    Severi, Stefano
    Ianniello, Annarita
    Sansovini, Maddalena
    Ambrosetti, Alice
    Bongiovanni, Alberto
    Scarpi, Emanuela
    Di Mauro, Francesca
    Rossi, Alice
    Matteucci, Federica
    Paganelli, Giovanni
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 (06) : 923 - 930
  • [34] Everolimus in Pancreatic Neuroendocrine Carcinomas G3
    Panzuto, Francesco
    Rinzivillo, Maria
    Spada, Francesca
    Antonuzzo, Lorenzo
    Ibrahim, Toni
    Campana, Davide
    Fazio, Nicola
    Delle Fave, Gianfranco
    [J]. PANCREAS, 2017, 46 (03) : 302 - 305
  • [35] A Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) S1609: The neuroendocrine cohort
    Patel, Sandip Pravin
    Othus, Megan
    Chae, Young Kwang
    Giles, Francis
    Hansel, Donna
    Singh, Preet
    Fontaine, Annette
    Shah, Manisha
    Kasi, Anup
    Al Baghdadi, Tareq
    Matrana, Marc
    Gatalica, Zoran
    Korn, W. Michael
    Hayward, Jourdain
    MMcLeod, Christine
    Chen, Helen X.
    Sharon, Elad
    Mayerson, Edward
    Ryan, Christopher W.
    Plets, Melissa
    Blanke, Charles D.
    Kurzrock, Razelle
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [36] Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology Well Differentiated Versus Poorly Differentiated
    Raj, Nitya
    Valentino, Emily
    Capanu, Marinela
    Tang, Laura H.
    Basturk, Olca
    Untch, Brian R.
    Allen, Peter J.
    Klimstra, David S.
    Reidy-Lagunes, Diane
    [J]. PANCREAS, 2017, 46 (03) : 296 - 301
  • [37] Capecitabine and temozolomide combination for treatment of high-grade, well-differentiated neuroendocrine tumour and poorly-differentiated neuroendocrine carcinoma - retrospective analysis
    Rogowski, Wojciech
    Wachula, Ewa
    Gorzelak, Anita
    Lebiedzinska, Aneta
    Sulzyc-Bielicka, Violeta
    Izycka-Swieszewska, Ewa
    Zolnierek, Jakub
    Kos-Kudla, Beata
    [J]. ENDOKRYNOLOGIA POLSKA, 2019, 70 (04) : 313 - 317
  • [38] Salvage PRRT with 177Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival
    Rudisile, S.
    Gosewisch, A.
    Wenter, V
    Unterrainer, M.
    Boening, G.
    Gildehaus, F. J.
    Fendler, W. P.
    Auernhammer, C. J.
    Spitzweg, C.
    Bartenstein, P.
    Todica, A.
    Ilhan, H.
    [J]. BMC CANCER, 2019, 19 (01)
  • [39] Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study
    Sorbye, H.
    Welin, S.
    Langer, S. W.
    Vestermark, L. W.
    Holt, N.
    Osterlund, P.
    Dueland, S.
    Hofsli, E.
    Guren, M. G.
    Ohrling, K.
    Birkemeyer, E.
    Thiis-Evensen, E.
    Biagini, M.
    Gronbaek, H.
    Soveri, L. M.
    Olsen, I. H.
    Federspiel, B.
    Assmus, J.
    Janson, E. T.
    Knigge, U.
    [J]. ANNALS OF ONCOLOGY, 2013, 24 (01) : 152 - 160
  • [40] Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3)
    Sorbye, Halfdan
    Baudin, Eric
    Borbath, Ivan
    Caplin, Martyn
    Chen, Jie
    Cwikla, Jaroslaw B.
    Frilling, Andrea
    Grossman, Ashley
    Kaltsas, Gregory
    Scarpa, Aldo
    Welin, Staffan
    Garcia-Carbonero, Rocio
    Arnold, Rudolf
    Bartsch, Detlef
    Baudin, Eric
    Bodei, Lisa
    Borbath, Ivan
    Capdevila, Jaume
    Caplin, Martyn
    Chen, Jie
    Costa, Frederico
    Lima, Regina
    Couvelard, Anne
    Cwikla, Jaroslaw B.
    Davies, Philippa
    de Herder, Wouter W.
    Falconi, Massimo
    Falkerby, Jenny
    Fazio, Nicola
    Ferone, Diego
    Frilling, Andrea
    Garcia-Carbonero, Rocio
    Glasberg, Simona
    Gorbunova, Vera
    Grossman, Ashley
    Hoersc, Dieter
    Jensen, Robert
    Kaltsas, Gregory
    Kloeppel, Guenter
    Tumors, Endocrine
    Knigge, Ulrich Peter
    Kos-Kudla, Beata
    Krejs, Guenter J.
    Krenning, Eric
    Kulke, Matthew
    Lamberts, Steven W. J.
    van Dijkum, Elisabeth Nieveen
    Manuel O'Connor, Juan
    O'Toole, Dermot
    Pape, Ulrich-Frank
    [J]. NEUROENDOCRINOLOGY, 2019, 108 (01) : 54 - 62